BACKGROUND: Laparoscopic cholecystectomy (LC) is the treatment of choice for acute cholecystitis. However, the morbidity and mortality rates are high in elderly patients or in those with co-morbidities at the time of surgery. Percutaneous cholecystostomy (PC) is a safe treatment for acute inflammation of the gall bladder. This study aimed to evaluate the safety and efficacy of PC for acute cholecystitis and investigate the post-PC factors leading to subsequent LC. MATERIALS AND METHODS: Ninety-three patients with acute cholecystitis who underwent PC between August 2006 and December 2012 were retrospectively reviewed for clinical course, outcomes, and prognosis. We evaluated patient age, the presence of co-morbidities, American Society of Anesthesiologists (ASA) score, duration of drainage of the PC tube, performance of LC, conversion rate, hospital stay, recurrence, and 30-day mortality. We compared these characteristics in two study groups: 31 were treated with only conservative PC (group I) and 62 with PC followed by elective LC (group II). RESULTS: Patients in group I were older than those in group II (80.38 ± 10.05 vs. 70.50 ± 11.81 years, p < 0.001). More group I patients had an ASA score of III or IV (deemed high risk for surgery) compared to group II patients (80.6 %, n = 25 vs. 37.0 %, n = 23, p = 0.0012). Age, ASA score, and cerebrovascular accident (CVA) were significantly correlated when analyzing factors used to decide surgery (R (2) = 0.15, p < 0.001; R (2) = 0.21, p < 0.001; R (2) = 0.05, p = 0.05, respectively). Two patients in group I died within 30 days. Six patients (19.3 %) in group I experienced recurrent cholecystitis after PC tube removal. CONCLUSIONS: PC is a safe and effective therapeutic option in high-risk patients with acute cholecystitis, or for preoperative management. The decisive risk factors for surgery after PC were age, ASA score, and CVA.
BACKGROUND: Laparoscopic cholecystectomy (LC) is the treatment of choice for acute cholecystitis. However, the morbidity and mortality rates are high in elderly patients or in those with co-morbidities at the time of surgery. Percutaneous cholecystostomy (PC) is a safe treatment for acute inflammation of the gall bladder. This study aimed to evaluate the safety and efficacy of PC for acute cholecystitis and investigate the post-PC factors leading to subsequent LC. MATERIALS AND METHODS: Ninety-three patients with acute cholecystitis who underwent PC between August 2006 and December 2012 were retrospectively reviewed for clinical course, outcomes, and prognosis. We evaluated patient age, the presence of co-morbidities, American Society of Anesthesiologists (ASA) score, duration of drainage of the PC tube, performance of LC, conversion rate, hospital stay, recurrence, and 30-day mortality. We compared these characteristics in two study groups: 31 were treated with only conservative PC (group I) and 62 with PC followed by elective LC (group II). RESULTS:Patients in group I were older than those in group II (80.38 ± 10.05 vs. 70.50 ± 11.81 years, p < 0.001). More group I patients had an ASA score of III or IV (deemed high risk for surgery) compared to group II patients (80.6 %, n = 25 vs. 37.0 %, n = 23, p = 0.0012). Age, ASA score, and cerebrovascular accident (CVA) were significantly correlated when analyzing factors used to decide surgery (R (2) = 0.15, p < 0.001; R (2) = 0.21, p < 0.001; R (2) = 0.05, p = 0.05, respectively). Two patients in group I died within 30 days. Six patients (19.3 %) in group I experienced recurrent cholecystitis after PC tube removal. CONCLUSIONS:PC is a safe and effective therapeutic option in high-risk patients with acute cholecystitis, or for preoperative management. The decisive risk factors for surgery after PC were age, ASA score, and CVA.
Authors: Masahiko Hirota; Tadahiro Takada; Yoshifumi Kawarada; Yuji Nimura; Fumihiko Miura; Koichi Hirata; Toshihiko Mayumi; Masahiro Yoshida; Steven Strasberg; Henry Pitt; Thomas R Gadacz; Eduardo de Santibanes; Dirk J Gouma; Joseph S Solomkin; Jacques Belghiti; Horst Neuhaus; Markus W Büchler; Sheung-Tat Fan; Chen-Guo Ker; Robert T Padbury; Kui-Hin Liau; Serafin C Hilvano; Giulio Belli; John A Windsor; Christos Dervenis Journal: J Hepatobiliary Pancreat Surg Date: 2007-01-30
Authors: Tyler J Loftus; Scott C Brakenridge; Frederick A Moore; Camille G Dessaigne; George A Sarosi; William J Zingarelli; Janeen R Jordan; Chasen A Croft; R Stephen Smith; Philip A Efron; Alicia M Mohr Journal: J Trauma Acute Care Surg Date: 2017-02 Impact factor: 3.313
Authors: Donna Marie L Alvino; Zhi Ven Fong; Colin J McCarthy; George Velmahos; Keith D Lillemoe; Peter R Mueller; Peter J Fagenholz Journal: J Gastrointest Surg Date: 2017-02-21 Impact factor: 3.452
Authors: Tyler J Loftus; Scott C Brakenridge; Camille G Dessaigne; George A Sarosi; William J Zingarelli; Frederick A Moore; Janeen R Jordan; Chasen A Croft; R Stephen Smith; Phillip A Efron; Alicia M Mohr Journal: World J Surg Date: 2017-05 Impact factor: 3.352
Authors: Francisco Schlottmann; Charles Gaber; Paula D Strassle; Marco G Patti; Anthony G Charles Journal: J Gastrointest Surg Date: 2018-09-17 Impact factor: 3.452
Authors: Charlotte S Loozen; Hjalmar C van Santvoort; Peter van Duijvendijk; Marc Gh Besselink; Dirk J Gouma; Grard Ap Nieuwenhuijzen; Johannes C Kelder; Sandra C Donkervoort; Anna Aw van Geloven; Philip M Kruyt; Daphne Roos; Kirsten Kortram; Verena Nn Kornmann; Apollo Pronk; Donald L van der Peet; Rogier Mph Crolla; Bert van Ramshorst; Thomas L Bollen; Djamila Boerma Journal: BMJ Date: 2018-10-08